WO1999042088A3 - Verfahren zur behandlung von erkrankungen oder störungen des innenohrs - Google Patents

Verfahren zur behandlung von erkrankungen oder störungen des innenohrs Download PDF

Info

Publication number
WO1999042088A3
WO1999042088A3 PCT/EP1999/001153 EP9901153W WO9942088A3 WO 1999042088 A3 WO1999042088 A3 WO 1999042088A3 EP 9901153 W EP9901153 W EP 9901153W WO 9942088 A3 WO9942088 A3 WO 9942088A3
Authority
WO
WIPO (PCT)
Prior art keywords
inner ear
sensory cells
disorders
cells
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/001153
Other languages
English (en)
French (fr)
Other versions
WO1999042088A2 (de
Inventor
Hubert Loewenheim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otogene AG
Original Assignee
Otogene AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP99910259A priority Critical patent/EP1056467B1/de
Priority to AT99910259T priority patent/ATE250936T1/de
Priority to DE59907195T priority patent/DE59907195D1/de
Priority to US09/622,719 priority patent/US7087581B1/en
Priority to DK99910259T priority patent/DK1056467T3/da
Priority to JP2000532105A priority patent/JP2002503687A/ja
Priority to CA002320717A priority patent/CA2320717C/en
Priority to AU29281/99A priority patent/AU763868B2/en
Application filed by Otogene AG filed Critical Otogene AG
Publication of WO1999042088A2 publication Critical patent/WO1999042088A2/de
Publication of WO1999042088A3 publication Critical patent/WO1999042088A3/de
Anticipated expiration legal-status Critical
Priority to US10/458,108 priority patent/US7132406B2/en
Priority to US11/588,910 priority patent/US7741303B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Bei einem Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs, die mit einer Schädigung oder Zerstörung von Sinneszellen des Innenohrs im Zusammenhang stehen, wird zur Regeneration der Sinneszellen mindestens ein Wirkstoff eingesetzt, der mindestens einen im Innenohr vorhandenen sogenannten Zellzyklus-Inhibitor in seiner inhibierenden Wirkung mindestens teilweise hemmt oder ausschaltet. Die Regeneration der Sinneszellen des Innenohrs erfolgt bei diesem Verfahren vorzugsweise durch Stimulation der Proliferation von Stützzellen. Bei den Sinneszellen des Innenohrs handelt es sich um die sogenannten Haarsinneszellen. Als Zellzyklus-Inhibitoren kommen Zyklinkinase-Inhibitoren wie insbesondere der Zyklinkinase-Inhibitor P27Kip1 in Frage.
PCT/EP1999/001153 1998-02-23 1999-02-23 Verfahren zur behandlung von erkrankungen oder störungen des innenohrs Ceased WO1999042088A2 (de)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA002320717A CA2320717C (en) 1998-02-23 1999-02-23 Method for the treatment of diseases or disorders of the inner ear
DE59907195T DE59907195D1 (de) 1998-02-23 1999-02-23 Verfahren zur behandlung von erkrankungen oder störungen des innenohrs
US09/622,719 US7087581B1 (en) 1998-02-23 1999-02-23 Method for the treatment of diseases or disorders of the inner ear
DK99910259T DK1056467T3 (da) 1998-02-23 1999-02-23 Metode til behandling af sygdomme eller lidelser i det indre øre
JP2000532105A JP2002503687A (ja) 1998-02-23 1999-02-23 内耳の疾患又は機能障害の治療方法
EP99910259A EP1056467B1 (de) 1998-02-23 1999-02-23 Verfahren zur behandlung von erkrankungen oder störungen des innenohrs
AT99910259T ATE250936T1 (de) 1998-02-23 1999-02-23 Verfahren zur behandlung von erkrankungen oder störungen des innenohrs
AU29281/99A AU763868B2 (en) 1998-02-23 1999-02-23 Method for the treatment of diseases or disorders of the inner ear
US10/458,108 US7132406B2 (en) 1998-02-23 2003-06-09 Stimulation of cellular regeneration and differentiation in the inner ear
US11/588,910 US7741303B2 (en) 1998-02-23 2006-10-27 Stimulation of cellular regeneration and differentiation in the inner ear

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19807426.3 1998-02-23
DE19807426A DE19807426A1 (de) 1998-02-23 1998-02-23 Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/024829 Continuation-In-Part WO2000023084A1 (en) 1998-02-23 1999-10-21 Methods for stimulating the regeneration of inner ear cells

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2000/005736 Continuation-In-Part WO2000054583A1 (en) 1998-02-23 2000-03-03 Methods for culturing fluid-filled sensory organs
US61409900A Continuation-In-Part 1998-02-23 2000-07-11

Publications (2)

Publication Number Publication Date
WO1999042088A2 WO1999042088A2 (de) 1999-08-26
WO1999042088A3 true WO1999042088A3 (de) 2000-03-02

Family

ID=7858563

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/001153 Ceased WO1999042088A2 (de) 1998-02-23 1999-02-23 Verfahren zur behandlung von erkrankungen oder störungen des innenohrs

Country Status (11)

Country Link
US (1) US7087581B1 (de)
EP (1) EP1056467B1 (de)
JP (1) JP2002503687A (de)
AT (1) ATE250936T1 (de)
AU (1) AU763868B2 (de)
CA (1) CA2320717C (de)
DE (2) DE19807426A1 (de)
DK (1) DK1056467T3 (de)
ES (1) ES2211055T3 (de)
PT (1) PT1056467E (de)
WO (1) WO1999042088A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530817A (ja) 1999-06-01 2003-10-21 ベイラー カレッジ オブ メディスン 聴覚障害、変形性関節症および細胞の異常増殖に関するａｔｏｎａｌ関連配列の治療用途のための組成物および方法
DE10027777A1 (de) * 2000-06-07 2001-12-13 Otogene Ag Transfektionsverfahren
CN1441841B (zh) * 2000-07-11 2013-03-20 桑得医药品公司 对内耳的细胞再生和分化的刺激
DE60332748D1 (de) 2002-10-02 2010-07-08 Anges Mg Inc Arzneimittel gegen hörfunktionsstörungen
EP1585523B1 (de) * 2002-12-17 2008-10-01 Centre National De La Recherche Scientifique (Cnrs) Verwendung von purinderivaten zur induktion der differenzierung überzähliger haarzellen und deiter-zellen im entwickelnden corti-organ zur behandlung von taubheit
WO2009147684A2 (en) 2008-06-06 2009-12-10 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
DE102010007281A1 (de) 2010-02-08 2011-08-11 EMC microcollections GmbH, 72070 Neue Aminoalkyl-oxazol- und Aminoalkyl-thiazolcarbonsäureamide und ihre Anwendung zur Stimulation der endogenen situ Regeneration von Haarsinneszellen im Corti'schen Organ des Innenohres beim Säuger
RU2480195C1 (ru) * 2011-11-02 2013-04-27 Федеральное государственное учреждение "Российский научный центр восстановительной медицины и курортологии Федерального агентства по здравоохранению и социальному развитию РФ" (ФГУ "РНЦВМиК Росздрава РФ") Способ лечения заболеваний внутреннего уха
BR112014016937A2 (pt) 2012-01-12 2017-06-13 Quark Pharmaceuticals Inc terapia de combinação para o tratamento de desordens de audição e do equilíbrio
US20150079110A1 (en) * 2012-03-05 2015-03-19 Wake Forest University Health Sciences Regeneration of inner ear cells
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017983A1 (en) * 1995-11-13 1997-05-22 Cambridge Neuroscience, Inc. Methods of treating disorders of non-visual sensory epithelia
WO1997022255A1 (en) * 1995-12-19 1997-06-26 Dana-Farber Cancer Institute p62 POLYPEPTIDES, RELATED POLYPEPTIDES, AND USES THEREFOR
WO1998000014A1 (en) * 1996-06-28 1998-01-08 The Regents Of The University Of California Transformation and genetherapy of cells of the inner ear
WO1998013048A1 (en) * 1996-09-27 1998-04-02 Trustees Of The University Of Pennsylvania Novel methods for inducing proliferation in auditory receptor epithelium
WO1999006064A1 (en) * 1997-07-30 1999-02-11 Amgen Inc. Method for preventing and treating hearing loss using a neurturin protein product

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19528388A1 (de) * 1995-08-02 1997-02-06 Hans Peter Prof Dr Med Zenner Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017983A1 (en) * 1995-11-13 1997-05-22 Cambridge Neuroscience, Inc. Methods of treating disorders of non-visual sensory epithelia
WO1997022255A1 (en) * 1995-12-19 1997-06-26 Dana-Farber Cancer Institute p62 POLYPEPTIDES, RELATED POLYPEPTIDES, AND USES THEREFOR
WO1998000014A1 (en) * 1996-06-28 1998-01-08 The Regents Of The University Of California Transformation and genetherapy of cells of the inner ear
WO1998013048A1 (en) * 1996-09-27 1998-04-02 Trustees Of The University Of Pennsylvania Novel methods for inducing proliferation in auditory receptor epithelium
WO1999006064A1 (en) * 1997-07-30 1999-02-11 Amgen Inc. Method for preventing and treating hearing loss using a neurturin protein product

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BUJIA J. ET AL: "Immunohistochemical detection of proliferating cell nuclear antigen in middle ear cholesteatoma.", EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, (1996) 253/1-2 (21-24)., XP002123938 *
CHEN, P. ET AL: "p27/Kip1, a cyclin -dependent kinase inhibitor, is required for the normal development of the mouse auditory sense organ.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, (1998) VOL. 24, NO. 1-2, PP. 809. MEETING INFO.: 28TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, PART 1 LOS ANGELES, CALIFORNIA, USA NOVEMBER 7-12, 1998 SOCIETY FOR NEUROSCIENCE., XP002123936 *
SCHWEITZER V G: "Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents.", LARYNGOSCOPE, (1993 APR) 103 (4 PT 2) 1-52. REF: 151, XP002123937 *
UMEMOTO M ET AL: "HAIR CELL REGENERATION IN THE CHICK INNER EAR FOLLOWING ACOUSIC TRAUMA: ULTRASTRUCTURAL AND IMMUNOHISTOCHEMICAL STUDIES", CELL AND TISSUE RESEARCH,DE,BERLIN, vol. 3, pages 435-443, XP002060017 *
YAMAGUCHI T ET AL: "The effect of chalone on the cell cycle in the epidermis during wound healing.", EXPERIMENTAL CELL RESEARCH, (1974 DEC) 89 (2) 247-54., XP002123939 *

Also Published As

Publication number Publication date
ATE250936T1 (de) 2003-10-15
CA2320717C (en) 2009-03-24
AU2928199A (en) 1999-09-06
DE19807426A1 (de) 1999-10-14
DK1056467T3 (da) 2004-02-09
PT1056467E (pt) 2004-02-27
EP1056467A2 (de) 2000-12-06
DE59907195D1 (de) 2003-11-06
US7087581B1 (en) 2006-08-08
WO1999042088A2 (de) 1999-08-26
JP2002503687A (ja) 2002-02-05
ES2211055T3 (es) 2004-07-01
EP1056467B1 (de) 2003-10-01
AU763868B2 (en) 2003-07-31
CA2320717A1 (en) 1999-08-26

Similar Documents

Publication Publication Date Title
IL144643A0 (en) Jak-3 inhibitors for treating allergic disorders
AU7186501A (en) Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
MXPA04005790A (es) Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona.
WO2002003872A3 (en) Application of photochemotherapy for the treatment of cardiac arrhythmias
EP1126855A4 (de) Methoden zur prophylaxe und behandlung von schäden der wahrnehmungshärchenzellenund der cochlearen neuronen
NO20023423L (no) Hjerne-, spinal- og nerveskade behandling
EA200200847A1 (ru) Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов
DE69936102D1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
ATE323482T1 (de) Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten
SI1578439T1 (sl) Postopki zdravljenja obolenj zaradi TNF-alfa aktivnosti z majhnimi dozami
WO1998010767A3 (en) Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
WO1999042088A3 (de) Verfahren zur behandlung von erkrankungen oder störungen des innenohrs
WO2004056307A3 (en) Disease treatment via antimicrobial peptide inhibitors
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
WO2000061167A3 (en) TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS
WO2001001974A3 (en) Naaladase inhibitors in anxiety and memory disorders
WO2001070737A3 (en) Therapeutic heterocyclic compounds for the treatment of asthma and allergy and use thereof
NO20016201L (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
WO2002004605A3 (en) Stimulation of cellular regeneration and differentiation in the inner ear
EP2016944A3 (de) Angiogenesisinhibitor enthaltend ein Rifampicinderivat
HK1048439A1 (zh) 用於治疗视神经及视网膜损伤之腺激酶抑制剂
PL376149A1 (en) Piperazine and piperidine derivatives for treatment of neurological diseases
WO2004056768A3 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
WO2000059940A3 (en) Platelet-derived growth factor related gene and protein
WO2000061125A3 (fr) L'osanetant dans le traitement des troubles de l'humeur

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2320717

Country of ref document: CA

Ref country code: CA

Ref document number: 2320717

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 29281/99

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999910259

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09622719

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999910259

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1999910259

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 29281/99

Country of ref document: AU